Bristol-Myers Squibb Company (BMY)
BMY stock forecast: what analysts expect
Wall Street analysts covering Bristol-Myers Squibb Company currently rate the stock a Buy on average, with a mean 12-month price target of $66.21 — +3.9% versus the last price of $63.70. Targets reflect analyst opinion, not a guarantee.
BMY historical returns
Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in BMY.
BMY annual returns by year
Congress trading in BMY
25 members of Congress have disclosed trading BMY — 23 purchases and 26 sales worth an estimated $639,504. Most recent disclosure: May 7, 2026.
See who in Congress traded BMY →About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
BMY Key Statistics
BMY in plain English
- P/E ratio (14.0) — how many dollars you pay for each $1 of BMY's yearly profit. That's on the low side, which can mean it's cheap — or that the market is worried.
- ROE (46.60%) — how efficiently the company turns shareholders' money into profit. Above ~20% is considered strong.
- Profit margin (18.87%) — of every $1 in sales, this is what's left as profit after all costs.
- Dividend yield (3.96%) — the cash payout you'd earn per year as a % of the share price, on top of any price gains.
BMY stock: frequently asked questions
What is Bristol-Myers Squibb Company's stock price today?
Bristol-Myers Squibb Company (BMY) last traded at $63.70 on the NYSE. Over the past 52 weeks the stock has traded between $42.52 and $68.10.
Is BMY stock a buy or a sell?
Wall Street analysts' consensus rating on BMY is "Buy", with an average 12-month price target of $66.21 — about +3.9% versus the current price of $63.70. Analyst targets are opinions, not guarantees; always do your own research.
How much would $1,000 invested in BMY 10 years ago be worth today?
A $1,000 investment in Bristol-Myers Squibb Company made 10 years ago would be worth about $1,579 today (dividends reinvested) — a total return of 58%, or 4.7% per year.
Does BMY pay a dividend?
Yes. Bristol-Myers Squibb Company currently pays a dividend yielding about 3.96% per year at today's share price.
What is BMY's P/E ratio?
BMY trades at a trailing price-to-earnings ratio of 14.0, and 9.7 times expected forward earnings. The P/E ratio tells you how many dollars investors pay for each $1 of the company's annual profit.
Do members of Congress trade BMY stock?
Yes — 25 members of Congress have disclosed trades in BMY under the STOCK Act, totaling 23 purchases and 26 sales worth an estimated $639,504.
What is Bristol-Myers Squibb Company's ticker symbol?
Bristol-Myers Squibb Company trades under the ticker symbol BMY on the NYSE.
Compare BMY with peers
Data last refreshed from public sources. Figures may be delayed. Not investment advice.